TherapeuticsMD Announces Third Quarter 2025 Financial Results
TXMD • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold TXMD in your mock portfolio yet.
The very high P/E ratio of 236.00 against a minimal EPS of 0.01 suggests the stock price embeds substantial expectations relative to current earnings power. Profitability exists but is extremely thin, implying that even small earnings disappointments could pressure the stock. With no additional revenue or margin data provided, the valuation looks stretched versus the underlying earnings profile.
The stock’s recent 5.8% gain over the last month and a price of $2.36 well above the 200-day moving average of $1.43 indicate a positive intermediate trend. However, the RSI at 65.89 is approaching overbought territory, suggesting upside may be more limited in the near term or vulnerable to consolidation. Overall, the technical setup is constructive but not without risk of a pullback.
Alternative data suggests limited external growth momentum. Website traffic is modest at an estimated 3,403 monthly visitors, hiring activity is flat at zero job openings, and social media followership is small with mixed trends. These signals collectively point to muted commercial traction and low external engagement, which does not strongly support a growth narrative at the current valuation.
Overall, the setup for TherapeuticsMD appears neutral: technical momentum is positive, but fundamentals and alternative data do not clearly justify the elevated valuation. The stock reflects optimism relative to very small current earnings, while external growth signals remain subdued. This mix supports a balanced stance rather than a distinctly bullish or bearish view.
TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Announces Second Quarter 2025 Financial Results

TherapeuticsMD Announces First Quarter 2025 Financial Results

TherapeuticsMD Announces Full Year 2024 Financial Results
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: